• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Matly David

    4/2/25 4:31:06 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INBX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Matly David

    (Last) (First) (Middle)
    C/O INHIBRX BIOSCIENCES, INC.
    11025 NORTH TORREY PINES ROAD, SUITE 140

    (Street)
    LA JOLLA CA 92037

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Inhibrx Biosciences, Inc. [ INBX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) (1) 05/30/2034 Common Stock 175,000 $15.86 D
    Explanation of Responses:
    1. Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
    Remarks:
    Exhibit 24.1 - Power of Attorney
    /s/ Kelly Deck, as attorney-in-fact for David Matly 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INBX

    DatePrice TargetRatingAnalyst
    7/23/2024Mkt Perform
    JMP Securities
    1/23/2024Mkt Outperform → Mkt Perform
    JMP Securities
    3/16/2022$40.00Outperform
    SMBC Nikko
    3/2/2022$53.00 → $40.00Market Outperform
    JMP Securities
    11/10/2021$44.00 → $53.00Outperform
    Credit Suisse
    11/2/2021$46.00 → $53.00Market Outperform
    JMP Securities
    9/21/2021$46.00Market Outperform
    JMP Securities
    More analyst ratings

    $INBX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Inhibrx Biosciences Inc.

      EFFECT - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      6/5/25 12:15:14 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Inhibrx Biosciences Inc.

      POS AM - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      6/2/25 4:11:04 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Inhibrx Biosciences Inc.

      424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)

      5/28/25 4:04:30 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Inhibrx Biosciences

      JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform

      7/23/24 6:28:37 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx downgraded by JMP Securities

      JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform

      1/23/24 7:21:49 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SMBC Nikko initiated coverage on Inhibrx with a new price target

      SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00

      3/16/22 7:49:54 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inhibrx Reports First Quarter 2025 Financial Results

      SAN DIEGO, May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.

      5/14/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

      SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered i

      4/1/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial state

      3/17/25 4:05:00 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kayyem Jon Faiz bought $1,523,620 worth of shares (107,186 units at $14.21) (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      11/22/24 4:03:55 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vuori Kristiina Md bought $100,005 worth of shares (6,667 units at $15.00), increasing direct ownership by 48% to 20,443 units (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      10/7/24 4:34:17 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Lappe Mark bought $629,117 worth of shares (40,000 units at $15.73) (SEC Form 4)

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      9/16/24 5:12:34 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Manhard Kimberly

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:35:52 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Vuori Kristiina Md

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:32:20 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kayyem Jon Faiz

      4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

      5/29/25 4:27:56 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Financials

    Live finance-specific insights

    See more
    • Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

      SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste

      10/4/22 8:00:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

      Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de

      5/16/22 9:00:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

      SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying caus

      10/12/21 7:30:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

      SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma.  We are building a seasoned, world-

      10/28/21 8:30:00 AM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inhibrx Biosciences Inc.

      SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)

      11/14/24 8:14:25 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

      SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

      2/14/24 5:09:31 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Inhibrx Inc. (Amendment)

      SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)

      2/14/24 5:01:36 PM ET
      $INBX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care